Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2003

View Archived Issues

Phytopharm reports quarterly development highlights

First-quarter progress at Medivir

Ciclosporin analogues for autoimmune diseases designed at Enanta

Memory Pharmaceuticals presents new PDE4 inhibitors for use in cognition disorders

Novel glucose-lowering 11CBy antagonists identified at GSK

Antitumor dolastatin derivative isolated and tested by Spanish researchers

Allergan patent covers new analgesic agents, their preparation and use

Bayer researchers present new adenosine uptake inhibitors

Scientists at Janssen identify new delta opioid receptor agonists

Checkpoint kinase inhibitors and their use as adjuvants in DNA-damaging cancer therapy

New antiobesity MCHR1 antagonists in GSK pipeline

Dietary omega n-3 LCPUFAs reduce the risk for AMD

Timolol-LA reported as effective as timolol maleate in reducing ocular hypertension

Regulatory approval sought for Fendrix

Theralux granted orphan drug status for CML

QLT discontinues phase III trials of tariquidar in NSCLC

Rifaximin does not promote antibacterial resistance in Salix study

At-home phase IIb study begins for ED treatment PT-141

Onconase to be tested in federal SARS program

Trillium Therapeutics approved as new name for Transplantation Technologies

IND filed for phase II trials of SPI-0211 in postoperative ileus

Phase IIa trial evaluates VR-004 delivered via lungs for ED

Dacogen granted fast track status for MDS

FDA advisory committee hands down favorable decision on atazanavir

Completely new approach to cancer treatment given the go-ahead by the FDA for multiple myeloma

Botanical product for hypertriglyceridemia unveiled at recent meeting

CellGate ciclosporin prodrug shows favorable PK and safety profile following topical administration

BM-573 prevents coronary artery thrombosis and myocardial infarction

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
Research grants support early clinical trials of ALS treatments
BioWorld Science
The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...